Contribute Try STAT+ Today

Good morning, everyone, how are you today? We are doing just fine, thank you, as sunny skies and cool breezes envelop the unusually quite Pharmalot campus. Our short person is hunched over a laptop once again for another day of learning and our official mascot is snoozing away in a corner. All of which means we are free to focus on the tasks at hand — brewing cups of stimulation and foraging for items of interest. On that note, here is the latest batch of tidbits. We hope your day goes well and you conquer the world. And of course, do stay in touch …

In a significant move to combat the Covid-19 pandemic, the U.S. government agreed to support a controversial proposal to temporarily waive intellectual property rights for vaccines in a bid to increase global supplies of desperately needed doses, STAT reports. Ultimately, a waiver would make it easier for countries that permit compulsory licensing to allow a manufacturer to export vaccines. The move came amid growing concern that low- and middle-income countries were being left out after wealthy nations reached deals with vaccine makers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.